Tags : Expansion

Novo Nordisk to Invest ~$117.4M in Expansion of its Production

Shots: Novo Nordisk to invest $117.4M in upgrading and expanding facilities at its production site in Kalundborg, Denmark The facilities currently develop diabetic therapies and will be rebuilt and expanded for the future production of these and the next generation of diabetic therapies. The projects are expected to be completed in 2022 The investment in […]Read More

Amgen Signs an Agreement with BeiGene for the Expansion of

Shots: Amgen acquires 20.5% stake in BeiGene for ~$2.8B in cash, with $174.85/share representing 36% premium. BeiGene will commercialize Xgeva, Kyprolis, and Blincyto in China with equal profit-loss sharing while two of them will revert to Amgen, after 5yrs. & 7yrs. BeiGene has the right to retain one product and will receive royalties on sales […]Read More

Thermo Fisher to Expand its Clinical Trials Capabilities and Collaborates

Shots: Thermo Fisher expands its clinical trials supply and distribution services network in China with the investment of $4.4M in its Suzhou facility to support the growth of clinical studies and to provide biotech companies with the resources to develop and commercialize new therapies in China Additionally, Thermo Fisher collaborates with Frontier to expedite the […]Read More

Mylan Launches Generic Faslodex Injection for the Expansion of its

Shots: Mylan launches Fulvestrant Injection (50 mg/mL)/single-dose prefilled syringe which is a generic version of AstraZeneca’s Faslodex Injection and has received FDA’s ANDA as monothx. for advanced BC in women with menopause and combination therapy for advance & m-BC The launch of Fulvestrant Injection expands Mylan’s oncology portfolio and available treatment options for women facing […]Read More

OncoCyte to Acquire Razor Genomics for the Expansion of its

Shots: OncoCyte acquires 25% stake in Razor and has an option to acquire its remaining shares. Razor to receive $10M for initial acquiring of 25% stock in its preferred share plus $1M as milestones based on its positive CMS coverage decision with its expected closure in end of September Post exercising the option, Razor to […]Read More

Jazz Pharmaceutical to Acquire Cavion for the Expansion of its

Shots: Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities The acquisition will broaden Jazz’s portfolio of sleep and neurological disorders and with the addition of Cavion’s CX-8998 it will further lead to expansion into movement […]Read More

Atricure to Acquire SentreHEART for Expansion of Therapies to Treat

Shots: Atricure acquires SentreHEART in all stock and cash transaction. Atricure to pay upfront as ~$40M in cash and AtriCure common stock, ~$140M milestones based on aMAZE IDE clinical trial including PMA approval, and ~$120M is based on a milestone related to reimbursement for the therapy involving SentreHEART devices The focus of the acquisition is […]Read More

STADA to Acquire GSK’s OTC Portfolio for the Expansion of

Shots: STADA acquires GSK’s six brands containing five skin care/topical application and one pediatric cough remedy namely Oilatum, Eurax, Savlon Antiseptic Cream, Ceridal, Tixylix and Polytar. The transaction is expected to close in Aug 2019 The focus of the acquisition is to strengthen and expand STADA’s Consumer Health business in European Healthcare markets. Additionally, the […]Read More

Pfizer to Acquire Therachon for the Expansion of its Rare

Shots: Pfizer acquires Therachon, in all stock transaction for $810M. Therachon to receive $340M upfront with additional payment on milestones of development and commercialization of its  TA-46 candidate targeted for achondroplasia Additionally, Therachon to spin-off its apraglutide development program into an independent firm, prior closure of the transaction. Pfizer Ventures to hold an equity stake […]Read More